Fig. 7.

NF-κB and Caspase-1 inhibition suppresses FynY531F-driven dopaminergic neuron loss and induction of il1b, il12a and irg1 expression. (A) Live confocal imaging of vDC eGFP-positive dopaminergic neurons in 5 dpf control dat:eGFP and dat:eGFP;elav:Gal4; UAS:fynY531F larvae show rescue of dopaminergic neuron loss after treatment with 0.5 µM caffeic acid phenethyl ester (CAPE; NF-κB inhibitor) and 20 µM Ac-YVAD-cmk (Caspase-1 inhibitor). (B) Quantification of vDC eGFP-positive cells (n=12). Analysis was performed using two-way ANOVA with Tukey's multiple comparison. (C,D) RT-qPCR revealed significantly reduced levels of il1b, il12a and irg1 after treatment of dat:eGFP;elav:Gal4; UAS:fynY531F larvae with 0.5 µM CAPE (C) and 20 µM Ac-YVAD-cmk (D). tnfa was increased after treatment with 0.5 µM CAPE and 20 µM Ac-YVAD-cmk (n=3 biological replicates for each genotype and condition). These experiments were performed together with the Saracatinib experiment in Fig. 4E, using shared untreated controls. Control data in these panels are also shown in Fig. 4E. Statistical analysis was performed with two-tailed unpaired Student's t-test. Bars represent mean±s.e.m. ns, not significant; *P<0.05; **P<0.01; ****P<0.0001. Scale bars: 50 µm.